.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a median follow-up of 11 months, patients along with metastatic gastrointestinal cysts that got biomarker-matched treatments based on flowing cyst DNA profiling revealed a higher professional benefit than those acquiring unmatched treatment.